Biomarin Pharmaceutical Inc (NASDAQ:BMRN)
| 78.40 BATS BZX Real-Time Price As of 3:25pm ET |  -0.78 / -0.98%Today’s Change | 68.25 Today|||52-Week Range 131.95 | -10.60% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $14.1B |
Company Description
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
Contact Information
BioMarin Pharmaceutical, Inc. 770 Lindaro Street San Rafael California 94901 |
Employees
Shareholders
| Mutual fund holders | 64.45% |
| Other institutional | 37.81% |
| Individual stakeholders | 1.81% |
Top Executives
| Jean-Jacques Bienaimé | Chairman & Chief Executive Officer |
| Brian R. Mueller | Chief Financial Officer & Executive Vice President |
| Eduardo E. Von Pervieux | Chief Information Officer |
| Henry J. Fuchs | President-Worldwide Research & Development |
| Steve Maricich | Medical Director-Clinical Sciences |
